(Total Views: 256)
Posted On: 10/24/2018 7:14:40 AM
Post# of 72433
Well that is good news. Looks like they weren’t scared to meet with the FDA after all as a self proclaimed PRO had mentioned. They found a means of financing that wouldn’t be with Aspire and its dilution. Remember most recent biotech partnerships don’t wait for signing until a milestone is achieved, they can pay when they occur with Contingent Value Rights (CVRs), and that can be for any achievement including BTD. So I’m thinking anytime folks.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)